%0 Journal Article
%A Mena-Vazquez, Natalia
%A Garcia-Studer, Aimara
%A Rojas-Gimenez, Marta
%A Romero-Barco, Carmen Maria
%A Manrique-Arija, Sara
%A Mucientes, Arkaitz
%A Velloso-Feijoo, Maria Luisa
%A Godoy-Navarrete, Francisco Javier
%A Morales-Garrido, Pilar
%A Redondo-Rodriguez, Rocio
%A Ordoñez-Cañizares, M C
%A Ortega-Castro, Rafaela
%A Lisbona-Montañez, Jose Manuel
%A Hidalgo Conde, Ana
%A Arnedo Diez de Los Rios, Rocio
%A Cabrera Cesar, Eva
%A Espildora, Francisco
%A Aguilar-Hurtado, Maria Carmen
%A Añón-Oñate, Isabel
%A Ureña-Garnica, Inmaculada
%A Fernandez-Nebro, Antonio
%T Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease.
%D 2022
%@ 2077-0383
%U http://hdl.handle.net/10668/21278
%X Objectives: To describe the frequency of COVID-19 and the effect of vaccination in patients with interstitial lung disease and systemic autoimmune disease (ILD-SAD) and to identify factors associated with infection and severity of COVID-19. Methods: We performed a cross-sectional multicenter study of patients with ILD-SAD followed between June and October 2021. The main variable was COVID-19 infection confirmed by a positive polymerase chain reaction (PCR) result for SARS-CoV-2. The secondary variables included severity of COVID-19, if the patient had to be admitted to hospital or died of the disease, and vaccination status. Other variables included clinical and treatment characteristics, pulmonary function and high-resolution computed tomography. Two logistic regression was performed to explore factors associated with “COVID-19” and “severe COVID-19”. Results: We included 176 patients with ILD-SAD: 105 (59.7%) had rheumatoid arthritis, 49 (27.8%) systemic sclerosis, and 22 (12.54%) inflammatory myopathies. We recorded 22/179 (12.5%) SARS-CoV-2 infections, 7/22 (31.8%) of them were severe and 3/22 (13.22%) died. As to the vaccination, 163/176 (92.6%) patients received the complete doses. The factors associated with SARS-CoV-2 infection were FVC (OR (95% CI), 0.971 (0.946−0.989); p = 0.040), vaccination (OR (95% CI), 0.169 (0.030−0.570); p = 0.004), and rituximab (OR (95% CI), 3.490 (1.129−6.100); p = 0.029). The factors associated with severe COVID-19 were the protective effect of the vaccine (OR (95% CI), 0.024 (0.004−0.170); p< 0.001) and diabetes mellitus (OR (95% CI), 4.923 (1.508–19.097); p = 0.018). Conclusions: Around 13% ofpatients with ILD-SAD had SARS-CoV-2 infection, which was severe in approximately one-third. Most patients with severe infection were not fully vaccinated.
%K SARS-CoV-2 infections
%K Interstitial lung disease (ILD)
%K Systemic autoimmune disease (SAD)
%K Vaccination COVID-19
%K Área de Gestión Sanitaria Sur de Sevilla
%~